



Contribution of Cancer-Targeting Drugs toward Faster Clinical Application 3.0

Guest Editor:

Prof. Dr. Sunpil Yoon

School of Pharmacy,
Sungkyunkwan University,
Suwon 16419, Republic of Korea

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Various cancer-targeting drugs (synthesized small molecules, natural products, antibodies, etc.) have been developed over the decades. These include: 1. general chemotherapeutic drugs that inhibit cell division and growth; 2. specific protein-targeting drugs that block overexpressed growth signaling, the abnormal production of ATP energy, or cancer-generated angiogenesis; and 3. cellular immunotherapeutic drugs that provide an enhanced attack on cancer cells.

In this Research Topic, we aim to identify and investigate the novel applications of cancer-targeting drugs, including: 1. products derived from original drugs, 2. drug repositioning, 3. experimental drugs soon to be available for testing in clinical trials, and 4. natural products. In our investigations, we also plan to include the pharmacokinetics and pharmacodynamics of combination drug treatments offering improvements over current therapies.

We expect that our findings will encourage the faster initiation of clinical trials as well as therapeutic application.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI